Revenue from Contracts with Customers

Revenue is recognized when control of the good or service is transferred to the customer either at a point in time or, in limited circumstances, as our services are rendered over time. Revenue is measured as the amount of consideration we expect to receive in exchange for transferring goods or services.



	Three Months Ended March 31, 2020
	Life Sciences		Mobile Solutions		Power Solutions		Intersegment Sales Eliminations			Total
United States and Puerto Rico	$	70,362	$	37,129	$	38,297	$	(588	)	$	145,200
China	2,038		7,692		1,157		—			10,887
Mexico	120		4,836		2,143		—			7,099
Brazil	—		8,583		130		—			8,713
Germany	5,610		2,150		39		—			7,799
Switzerland	3,032		931		21		—			3,984
Other	2,886		8,563		4,614		—			16,063
Total net sales	$	84,048	$	69,884	$	46,401	$	(588	)	$	199,745



	Three Months Ended March 31, 2019
	Life Sciences		Mobile Solutions		Power Solutions		Intersegment Sales Eliminations			Total
United States and Puerto Rico	$	68,343	$	44,457	$	41,115	$	(484	)	$	153,431
China	1,692		9,153		1,838		—			12,683
Mexico	127		5,378		2,709		—			8,214
Brazil	—		8,382		69		—			8,451
Germany	8,885		1,406		16		—			10,307
Switzerland	3,265		1,359		16		—			4,640
Other	3,696		7,940		3,894		—			15,530
Total net sales	$	86,008	$	78,075	$	49,657	$	(484	)	$	213,256

Deferred Revenue

The following table provides information about contract liabilities from contracts with customers.



	Deferred Revenue
Balance at January 1, 2020	$	4,172
Balance at March 31, 2020	$	3,168

Revenue recognized during the three months ended March 31, 2020, from amounts included in deferred revenue at the beginning of the period for performance obligations satisfied or partially satisfied during the period, was $1.0 million.

Transaction Price Allocated to Future Performance Obligations

We are required to disclose the aggregate amount of transaction price that is allocated to performance obligations that have not yet been satisfied as of March 31, 2020, unless our contracts meet one of the practical expedients. Our contracts met the practical expedient for a performance obligation that is part of a contract that has an original expected duration of one year or less.

Sales Concentration

We recognized sales from a single customer of $25.6 million, or 13% of consolidated net sales, during the three months ended March 31, 2020, and $23.3 million, or 11% of consolidated net sales, during the three months ended March 31, 2019. Revenues from this customer are in our Life Sciences and Power Solutions groups.